AI Investment Decisions in Life Sciences

An executive apéro in Basel for senior leaders from pharma, biotech and medtech. The conversation is private and off the record. It's about how AI investment decisions are actually made at the executive level.

The question on the table If you had to justify a major AI investment today, how would you frame the decision?
We'll talk about how leaders weigh strategic priorities and risk, from sustaining current performance to accelerating future launches. We'll also cover whether to build, buy or partner, and a newer option: investing directly in AI startups. What does that look like in a regulated industry? Where are the real tradeoffs, and which models work for R&D, Commercial Ops or Tech Ops?
Who is at the table CEOs and C-level executives (CTO, CIO, CDO), VPs and board members from life sciences companies across Switzerland. We keep it to 15 participants max, so you get to know everyone at the table.
When: Monday, 26 October 2026, 18:30 – 20:30 Where: Nomad Hotel Basel Tickets: CHF 5, free for TechLounges patrons. We review every registration before confirming it, to keep the group balanced.

Register here: https://luma.com/l09kirf4
Questions: [email protected]
Organized by TechLounges Association, Basel.